title: Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.
abstract: Agonists for the neurotensin NTS₁ receptor consistently exhibit antipsychotic effects in animal models without producing catalepsy, suggesting that NTS₁-receptor agonists may be a novel class of drugs to treat schizophrenia. Moreover, studies utilizing NTS₁ agonists have reported improvements in some aspects of cognitive functioning, including prepulse inhibition and learning procedures, which suggest an ability of NTS₁-receptor agonists to diminish neurocognitive deficits. The present study sought to assess both baseline delay-induced memory performance and the effects of NTS₁-receptor activation on learning and memory consolidation in male Long-Evans and Brown Norway rats using a delayed nonmatch-to-position task radial arm-maze task. In the absence of drugs, Brown Norway rats displayed a significant increase in spatial memory errors following 3-, 7-, and 24-hr delay, whereas Long-Evans rats exhibited an increase in spatial memory errors following only a 7-, and 24-hr delay. With Brown Norway rats, administration of PD149163 before or after an information trial significantly reduced errors during a retention trial after a 24 hr delay. Administration of the NTS(1/2)-receptor antagonist SR142948 prior to the information trial did not affect retention-trial errors. These data are consistent with previous findings that Brown Norway rats have natural cognitive deficits and that they may be useful for assessing putative antipsychotic drugs for cognitive efficacy. Moreover, the results of this study support previous findings suggesting that NTS₁-receptor agonists may improve some aspects of cognitive functioning.
authors.affiliation: Psychology Department, Northern Michigan University.
authors.forename: Ashley A
authors.initials: AA
authors.lastname: Keiser
authors.affiliation: Psychology Department, Northern Michigan University.
authors.forename: Katelin S
authors.initials: KS
authors.lastname: Matazel
authors.affiliation: Psychology Department, Northern Michigan University.
authors.forename: Melissa K
authors.initials: MK
authors.lastname: Esser
authors.affiliation: Department of Psychiatry, University of California San Diego.
authors.forename: David
authors.initials: D
authors.lastname: Feifel
authors.affiliation: Psychology Department, Northern Michigan University.
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Prus
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects; D003071:Cognition / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007279:Injections, Subcutaneous; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008569:Memory Disorders / Q000188:drug therapy*; D057567:Memory, Long-Term / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects; D009496:Neurotensin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011720:Pyrazoles / Q000633:toxicity; D011804:Quinolines / Q000633:toxicity; D011914:Rats, Inbred BN; D020318:Rats, Long-Evans; D018028:Receptors, Neurotensin / Q000819:agonists* / Q000037:antagonists & inhibitors; D012153:Retention, Psychology / Q000187:drug effects; D065852:Spatial Memory / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D018697:Nootropic Agents; C117269:PD 149163; D011720:Pyrazoles; D011804:Quinolines; D018028:Receptors, Neurotensin; C114947:SR 142948; C114036:neurotensin type 1 receptor; D009496:Neurotensin